Biopharmaceutical research companies are conducting or have conducted more than 4,700 clinical trials of new medicines in collaboration with the state’s clinical research centers, university medical schools and hospitals (1999 to present).
In South Carolina, more than 4,700 clinical trials since 2004 have targeted diseases and conditions like asthma, arthritis, cancer, diabetes, cardiovascular disease and Alzheimer’s disease.
“SCBIO’s mission to build, advance, and grow the life sciences industry in South Carolina is heavily driven by the incredible $11.4 billion economic impact this industry has on the palmetto state, as the fastest growing segment of our innovation economy—with biopharma being a crucially important contributor. Beyond the stunning economic impact, the ultimate goal is to continually generate new breakthrough solutions catalyzed by research efforts, that support new drug development and vital clinical trials that can extend life, enhance quality of life, and relieve suffering for patients everywhere. We are immensely grateful for dynamic partnerships between industry, researchers, health care organizations, and associations like PhRMA and SCBIO that energize and fuel these compelling missions—that ultimately impact each of us and our loved ones at the most personal level.” --Sam Konduros, president & CEO, SCBIO